Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02867384 · ClinicalTrials.gov registry record · Phase 2
Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
A Phase 2 study of Graft Vs Host Disease, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
- 5
- Study locations
NCT02867384 is a Phase 2 study of Graft Vs Host Disease that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 181 participants, above the 133-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (36% higher). The trial reports 5 study locations across 4 states.
The verdict
NCT02867384, a Phase 2 study of Graft Vs Host Disease, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
- 5
- Study locations
Study Summary
This research study is studying a drug called obinutuzumab as a means of preventing chronic Graft vs. Host Disease (cGVHD).
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Placebo
Study Locations (5)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
California
- Stanford University - Palo Alto
Minnesota
- Masonic Cancer Center - Minneapolis
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2016-11-29 |
| Est. Completion | 2024-11-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02867384
The ClinicalTrials.gov registry entry for NCT02867384 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 133-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (36% higher). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Graft Vs Host Disease appearing as the primary indexed condition, and to 2 interventions - of which Obinutuzumab is the first listed.
NCT02867384 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02867384 about?
NCT02867384 is a clinical study titled "Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation". This research study is studying a drug called obinutuzumab as a means of preventing chronic Graft vs. Host Disease (cGVHD).
What is the current status of trial NCT02867384?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2016-11-29. Estimated completion is 2024-11-14.
What conditions does trial NCT02867384 study?
This clinical trial studies the following conditions: Graft Vs Host Disease.
What interventions are being tested in trial NCT02867384?
The interventions under investigation include: Obinutuzumab (DRUG), Placebo (DRUG).
Who is sponsoring clinical trial NCT02867384?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02867384 being conducted?
This trial has 5 study locations across California, Massachusetts, Minnesota, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 2
-
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RECRUITING · Phase 2
-
Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
RECRUITING · Phase 2
-
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
ACTIVE NOT RECRUITING · Phase 2
-
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
ACTIVE NOT RECRUITING · Phase 2
-
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.